Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, has collaborated with CrystecPharma in the Advanced Manufacturing Supply Chain Initiative (AMSCI) to create a new platform that would boost drug development programmes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Juniper Pharma Services is a contract development and manufacturing organisation.
Juniper Pharma Services senior vice-president Dr Claire Madden-Smith said: “Our progress on the AMSCI project with CrystecPharma and other consortium partners brings us within reach of a commercially viable platform for the advanced manufacturing of next generation medicines.”
CrystecPharma’s supercritical fluid technology platform is currently on-site at the Juniper Pharma Services facility, where Validation is being performed to facilitate its use in the development of clinical trial materials.
The multi-partner project has been designed to move medicines from research to the market at a much greater speed and with enhanced quality.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe project focuses on producing new drug substance to good manufacturing practice (GMP) standard at Juniper’s manufacturing facility in Nottingham by the end of summer.
CrystecPharma chief executive officer Paul Thorning said: “Our equipment combined with Juniper’s expertise is the only project of its type in the world and is truly innovative in terms of using modified supercritical fluid technology (mSAS) for the manufacture of smarter, higher quality pharmaceutical products.
“The sum of the consortium is certainly stronger than its individual parts and the AMSCI is reinforcing the UK’s position as the best in the world at drug development innovation.”
The supercritical fluid technology, which focuses on drug developers with combination products and compounds that are hard to crystallise, has been created to manufacture drug substances of improved quality.
With less optimisation required versus traditional development platforms, the technology facilitates quicker scale-up from animal studies to human-ready batches.
Image: Juniper Pharma Services senior vice-president Dr Claire Madden-Smith. Photo: courtesy of Juniper Pharmaceuticals.
